Entrada Therapeutics's top three insider shareholders as of March 23, 2026 are Todd Foley (Director, 4.43Mn shares), Bioventures 2018, L.P. Mpm (TenPercentOwner, 4.38Mn shares), Ventures V, L.P. 5Am (TenPercentOwner, 2.96Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Todd Foley | 0 | 4,425,784 | 04 Nov, 2021 | |
| Bioventures 2018, L.P. Mpm | 0 | 4,381,062 | 12 Dec, 2024 | |
| Ventures V, L.P. 5Am | 2,963,066 | 0 | 18 Nov, 2025 | |
| Kush Parmar | 0 | 2,963,066 | 18 Nov, 2025 | |
| Holding Ltd Roche | 0 | 2,813,525 | 04 Nov, 2021 | |
| Group, Llc Redmile | 0 | 1,954,420 | 04 Nov, 2021 | |
| Ventures V, L.P. 5Am | 0 | 1,093,313 | 11 Jul, 2025 | |
| Dipal Doshi | Ceo | 526,014 | 0 | 03 Mar, 2026 |
| Natarajan Sethuraman | President, Research Develop. | 242,224 | 0 | 03 Mar, 2026 |
| Nathan J Dowden | President Coo | 198,588 | 0 | 11 Mar, 2026 |
| Kory James Wentworth | Chief Financial Officer | 121,510 | 0 | 11 Mar, 2026 |
| Peter S Kim | 104,330 | 0 | 05 Jun, 2024 | |
| Nerissa Kreher | Chief Medical Officer | 40,037 | 0 | 06 Sep, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Mar, 2026 | Kory James Wentworth | Common Stock | D | 5,089 | $13.00 | 132,898 | D | S |
| 09 Mar, 2026 | Nathan J Dowden | Common Stock | D | 3,116 | $13.02 | 210,482 | D | S |
| 10 Mar, 2026 | Nathan J Dowden | Common Stock | D | 11,894 | $13.05 | 198,588 | D | S |
| 10 Mar, 2026 | Kory James Wentworth | Common Stock | D | 11,388 | $13.02 | 121,510 | D | S |
| 04 Mar, 2026 | Kory James Wentworth | Common Stock | D | 7,988 | $12.25 | 137,987 | D | S |
| 01 Mar, 2026 | Kory James Wentworth | Common Stock | A | 44,600 | $0.00 | 154,626 | D | A |
| 01 Mar, 2026 | Natarajan Sethuraman | Common Stock | A | 55,800 | $0.00 | 253,699 | D | A |
| 01 Mar, 2026 | Dipal Doshi | Common Stock | A | 139,400 | $0.00 | 555,064 | D | A |
| 01 Mar, 2026 | Nathan J Dowden | Common Stock | A | 55,800 | $0.00 | 234,859 | D | A |
| 02 Mar, 2026 | Nathan J Dowden | Common Stock | D | 7,223 | $11.66 | 227,636 | D | F |
| 02 Mar, 2026 | Natarajan Sethuraman | Common Stock | D | 3,898 | $11.66 | 249,801 | D | F |
| 02 Mar, 2026 | Kory James Wentworth | Common Stock | D | 2,939 | $11.66 | 151,687 | D | F |
| 02 Mar, 2026 | Dipal Doshi | Common Stock | D | 9,869 | $11.66 | 545,195 | D | F |
| 03 Mar, 2026 | Natarajan Sethuraman | Common Stock | D | 7,577 | $11.76 | 242,224 | D | F |
| 03 Mar, 2026 | Dipal Doshi | Common Stock | D | 19,181 | $11.76 | 526,014 | D | F |
| 03 Mar, 2026 | Kory James Wentworth | Common Stock | D | 5,712 | $11.76 | 145,975 | D | F |
| 03 Mar, 2026 | Nathan J Dowden | Common Stock | D | 14,038 | $11.76 | 213,598 | D | F |
| 01 Mar, 2026 | Natarajan Sethuraman | Stock Option (Right to Buy) | A | 83,200 | $0.00 | 83,200 | D | A |
| 01 Mar, 2026 | Nathan J Dowden | Stock Option (Right to Buy) | A | 83,200 | $0.00 | 83,200 | D | A |
| 01 Mar, 2026 | Kory James Wentworth | Stock Option (Right to Buy) | A | 66,600 | $0.00 | 66,600 | D | A |